Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.
Terufumi Kato
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Takashi Seto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Makoto Nishio
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Koichi Goto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Shinji Atagi
Honoraria - Chugai Pharma
Yukio Hosomi
Honoraria - Chugai Pharma
Noboru Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Toyoaki Hida
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca; Nippon Boehringer Ingelheim
Honoraria - Chugai Pharma
Research Funding - Nippon Boehringer Ingelheim
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Seisuke Nagase
No relevant relationships to disclose
Isamu Okamoto
Honoraria - Chugai Pharma
Takeharu Yamanaka
Honoraria - Chugai Pharma
Ryosuke Harada
Employment or Leadership Position - Chugai Pharma
Masahiro Fukuoka
Honoraria - Chugai Pharma
Nobuyuki Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma